Showing results (451-460 of 4,634) with videos related to
Sort By:
Pageof 464
Anti-Cancer Drugs|August 27, 2016
Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinibKazuyuki Numakura, Norihiko Tsuchiya, Hideaki Kagaya, et al.Anti-Cancer Drugs|May 26, 2017
Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancerAdam Pendlebury, Robert DeBernardo, Peter G RoseAnti-Cancer Drugs|May 26, 2017
Hypoxia as a target for drug combination therapy of liver cancerCressida Bowyer, Andrew L Lewis, Andrew W Lloyd, et al.Anti-Cancer Drugs|May 26, 2017
Role of the uridine/cytidine kinase 2 mutation in cellular sensitiveness toward 3'-ethynylcytidine treatment of human cancer cellsAkira Sato, Takeshi Takano, Akiko Hiramoto, et al.Anti-Cancer Drugs|June 14, 2017
Blockade of GLUT1 by WZB117 resensitizes breast cancer cells to adriamycinQing Chen, Ya-Qiu Meng, Xiao-Fan Xu, et al.Anti-Cancer Drugs|March 12, 2010
Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic reviewAdrian Yun-San Yip, Lap-Ah Tse, Eleanor Yuen-Yuen Ong, et al.Anti-Cancer Drugs|February 1, 1994
A rapid mechanism-based screen to detect potential anti-cancer agentsD S Swaffar, C M Ireland, L R BarrowsAnti-Cancer Drugs|February 1, 1994
Anti-tumor efficacy of glutaminase-copper-ATP combination in mice bearing Ehrlich ascites carcinomaS Pal, P MaityAnti-Cancer Drugs|February 1, 1994
Cellular accumulation and DNA damage induced by liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum+ ++(II) in LoVo and LoVo/PDD cellsI Han, T Nguyen, L Y Yang, et al.Anti-Cancer Drugs|February 1, 1994
Intravesical mitoxantrone for superficial bladder tumorsL S Yaman, T Yurdakul, N P Zissis, et al.Pageof 464